1. What is the decision or change (e.g. clinical topic, practice guideline, system design, delivery of care) you are facing or struggling with where a summary of the evidence would be helpful?

We're interested in the benefits and harms of local and regional liver-directed therapies, including transarterial therapies chemoembolization (TACE), bland embolization, and radioembolization, external beam radiation therapy, and adjuvant therapy, for locally advanced hepatocellular carcinoma.

2. Why are you struggling with this issue?

This gap in the American Society of Clinical Oncology guidelines portfolio for locally advanced HCC was identified by both a recent guideline panel working on advanced HCC, and by our Gastrointestinal Guidelines Advisory Group, which prioritized this topic in October 2023. This topic is important because it is an evolving area, and there have been new developments, for example the combination of local and systemic therapies. ASCO feels that society members would benefit from guidance on this topic in order to raise awareness of these therapy options and ultimately increase their utilization, while reducing practice variation.

3. What do you want to see changed? How will you know that your issue is improving or has been addressed?

We would like to see improved uptake and appropriate use of the use of the local and regional therapies listed previously in order to improve outcomes for patients with locally advanced hepatocellular carcinoma. We hope to accomplish this by widely disseminating a clinical practice guideline based on this review.

4. When do you need the evidence report?

Tue, 12/31/2024

5. What will you do with the evidence report?

This report will be used as the evidence-base for an ASCO clinical practice guideline, which will be published in the Journal of Clinical Oncology, and published with associated tools and resources on the ASCO web site.

Optional Information About You

What is your role or perspective? Professional Society Staff

If you are you making a suggestion on behalf of an organization, please state the name of the organization American Society of Clinical Oncology

May we contact you if we have questions about your nomination? Yes